Drug Approval | April 07, 2024
Eugia Steriles gets 3 observations from USFDA for injectable facility
The observations are procedural in nature and will be responded to within the stipulated time
The observations are procedural in nature and will be responded to within the stipulated time
Eugia Pharma Specialities restarts production at terminally sterilized product lines
The product is expected to be launched in December 2023
The product is expected to be launched in FY25
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
The product is being launched in August 2023
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
The product is expected to be launched by Q4 FY23.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)